Aspen leaps on JSE as suitors offer to buy parts of its business
Interest in its active pharmaceutical ingredients operations, excluding French arm, which generated R6.4bn revenue in financial 2021
Aspen says it has received two unsolicited offers to buy parts of its global active pharmaceutical ingredients (API) business, which manufacturers active ingredients used in medications. Its share price leapt the most in more than four months.
The manufacturing business has operations in SA, the Netherlands and the US, the company said. The offer excluded a French manufacturing facility that also produces APIs...